Sangui BioTech:

• Increase in Sales of USD 182% in fiscal year 2025
• Positive operating result and positive annual result

Hamburg, September 26, 2025:
In the fiscal year 2025 (01/07/2024 to 30/06/2025) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 375,787. In the same period of the previous year the comparable revenue amounted to USD 133,345. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2025 increased by 182% compared to the previous year.

Operating expenses increased to USD 24,969 or 18% to USD 159,836. As a result of the above factors, the operating result increased USD 217,746 to USD 215,951. Due to the lower exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate losses from the valuation of loans denominated in EURO, the gain of the year increased by USD 81,452 to USD 69,312 accordingly.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink marketplace operated by OTC Markets Group Inc. Companies are current in their reporting and undergo an annual verification and management certification process. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

---